Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Valeria Santini, Rami Komrokji, Michael Savona, Maria Diez-Campelo, Pierre Fenaux, Mikkael Sekeres, Yazan Madanat, David Valcarcel, Anna Jonasova, Petra Belohlavkova, Tymara Berry, Souria Dougherty, Sheetal Shah, Qi Xia, Libo Sun, Ying Wan, Fei Huang, Faye Feller, Shyamala Navada, Amer Zeidan, Uwe Platzbecker
Institutions: Azienda Ospedaliero-Universitaria Careggi, University of Florence, Moffitt Cancer Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Hôpital Saint-Louis, Université Paris Diderot, University of Miami, Sylvester Comprehensive Cancer Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Vall d'Hebron Hospital Universitari, Charles University, University Hospital Hradec Králové, Yale Cancer Center, Yale University, University Hospital Carl Gustav Carus, Nationales Centrum für Tumorerkrankungen Dresden, Technische Universität Dresden
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417013408